AZD1152-Barasertib-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAZD1152Cat. No.: HY-10127CAS No.: 722543-31-9Synonyms: Barasertib分式: CHFNOP分量: 587.54作靶點(diǎn): Aurora Kinase作通路: Cell Cycle/DNA Damage; Epigenetics儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO :

2、 33 mg/mL (56.17 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.7020 mL 8.5101 mL 17.0201 mL5 mM 0.3404 mL 1.7020 mL 3.4040 mL10 mM 0.1702 mL 0.8510 mL 1.7020 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄的?chǔ)備液，再依次添加助溶

3、劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.17 mg/mL (3.69 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.17 mg/mL (3.69 mM); Clear solution1/3 Master of Small

4、Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.17 mg/mL (3.69 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 AZD1152Barasertib-hQPA 的前體藥物， 度選擇性的 Aurora B 抑制劑，IC50 值為 0.37 nM。IC50 & Target Aurora B0.37 nM (IC50)體外研究 AZD1152 displays 3000-fold selectivity for Aurora B as comp

5、ared with Aurora A which has an IC50 of 1.368M. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3,JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4,MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and

6、 K562 cells with IC50 of 3-40 nM, displaying appr100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 M. AZD1152inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, aswell as the freshly isolated imatinib-resistant leu

7、kemia cells with IC50 values of 1-3 nM, more significantlycompared with bone marrow mononuclear cells with IC50 values of 10 nM. AZD1152 induces accumulationof cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner 1. AZD1152causes significant accumulation of cells

8、with 4N/8N DNA content in KMS12 and U266 and induces apoptosisin KMS18 and U266. AZD1152 in combination with DEX, has negative effects on cell viability in comparisonwith single agent in PMI8226, KMS11 and U266 3.體內(nèi)研究 Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM1

9、3 xenografts,confirmed by the observation of necrotic tissue with infiltration of phagocytic cells 1. In addition, AZD1152(10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, includingcolon, breast, and lung cancers, in a dose-dependent manner 2. AZD1152

10、 (25 mg/kg/day) treatmentreduces xenograft levels such that they are slightly lower levels than after the first round of treatment, but thisis not statistically significant indicating that residual cells might be more resistant to a second cycle ofAZD1152 4.PROTOCOLCell Assay 3 Approximately 1105 ce

11、lls in RPMI media with 10% FBS media are plated per well in a treated 96-well plateat 24-h intervals for up to 120 h (in triplicate for each time-point). For each timepoint, 20 L of MTS reagent3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner saltsolutio

12、n is added to each well and incubated at 37C for 4 h. The plate absorbance is read at 490 nm on a96-well spectra max 190 Plate Reader using Softmax Pro 4.8 Software. MTS solution is added to media-onlywells to correct for background. Setting the control cells at 100% viability, the viability of cell

13、s treated withvarious concentrations of siRNA or drug is determined and graphed using MS Excel.MCE has not independently confirmed the accuracy of these methods. They are for reference only.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEAnimal Female immune-deficient BALB/c nude mice at 4 weeks of

14、 age are purchased from JAPAN SLC and areAdministration 1 maintained in pathogen-free conditions with irradiated chow. Animals are bilaterally, subcutaneously injectedwith 2106 MOLM13 cells/tumor in 0.1 mL Matrigel. When MOLM13 cells formed palpable tumors, mice aredivided randomLy into control (n=5

15、) and treatment groups (n=5), and treatment is begun. AZD1152 (5 or 25mg/kg) with or without vincristine (0.2 mg/kg) is given to mice by intraperitoneal injection 4 times a week orevery another day, respectively. Daunorubicin (1 mg/kg) is given to mice by intraperitoneal injection 6 timesduring 2 we

16、eks of treatment either alone or in combination with AZD1152 (5 mg/kg). The dose of theseagents is determined by our preliminary studies. Control diluent is given to the untreated control mice. Bodyweight and tumors are measured twice a week. Tumor sizes are calculated. At the end of the experiment,

17、animals are killed by CO2 asphyxiation and tumor weights are measured after their careful resection. Tumortissue is collected for analysis.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Science. 2017 Dec 1;358(6367). Nat Commun. 2019 Apr 18

18、;10(1):1812 Clin Cancer Res. 2019 Jul 15;25(14):4552-4566. Patent. US20180263995A1. Harvard Medical School LINCS LIBRARYSee more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Yang J, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulindepolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep2. Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xe